Quadrivalent human papillomavirus vaccination before pregnancy and pregnancy outcomes: nationwide, population based case-control study.

Quadrivalent human papillomavirus vaccination before pregnancy is linked to a 5-15% reduction in adverse pregnancy outcomes, especially among women vaccinated at younger ages.

• Why it matters: Understanding the safety and potential benefits of HPV vaccination before pregnancy is crucial, as concerns about adverse outcomes may influence vaccination rates and public health strategies.
• What they did: The study analyzed data from 624,713 singleton births in Sweden between 2006 and 2023, using matched case-control methods and logistic regression to assess associations between HPV vaccination and pregnancy outcomes.
• The result: Findings indicate that HPV vaccination prior to pregnancy is associated with decreased odds of preterm birth, spontaneous preterm birth, preterm prelabour rupture of membranes, and severe small for gestational age infants, supporting vaccination benefits beyond cancer prevention.